Jeannie Shen was appointed medical director of the Breast Program at Huntington Hospital, an affiliate of Cedars-Sinai, and medical director of the International Health Program at Cedars-Sinai Cancer at Huntington Hospital.
Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment.
